Sixteen major pharmaceutical companies have reached agreements with the Trump administration to align American prescription drug costs with prices charged in other developed countries, securing three-year exemptions from import tariffs in return.
The pharmaceutical manufacturers have committed to implementing “most-favoured-nation” pricing strategies, offering medications directly to patients via a newly established government website called TrumpRx.gov, and pledging substantial investments in U.S. operations.
Last July, President Trump sent correspondence to leaders of 17 major pharmaceutical corporations, requiring them to align their U.S. drug pricing with the lowest rates available in other developed countries. Sixteen companies have publicly confirmed their participation in these arrangements.
PFIZER
In September, the pharmaceutical giant committed to reducing prescription medication costs for American consumers, offering discounts reaching 85% through the TrumpRx.gov platform.
The company stated that most of its primary care medications and select brand-name drugs, including the rheumatoid arthritis treatment Xeljanz, dermatitis medication Eucrisa, and post-menopausal osteoporosis drug Duavee, will feature average price reductions of 50%, with potential savings reaching 85%.
JOHNSON & JOHNSON
In January, the healthcare corporation agreed to reduce medication prices for American consumers, including offerings through the TrumpRx.gov website.
The company has not revealed specific agreement details, including information about adjusted pricing or covered medications.
ASTRAZENECA
The British-Swedish pharmaceutical company committed in October to lowering prescription drug costs for American patients, providing discounts up to 80% via TrumpRx.gov.
NOVO NORDISK
The Danish diabetes and weight-loss medication manufacturer agreed in November to decrease pricing for its semaglutide products, including Wegovy and Ozempic, for American consumers through Medicare, Medicaid, and direct-payment options.
Monthly costs for Ozempic and Wegovy will drop from $1,000 and $1,350 respectively to $350 when purchased via TrumpRx.
The company will also supply commonly prescribed insulin medications, including NovoLog and Tresiba, at $35 monthly through TrumpRx.
ELI LILLY
In November, the Indianapolis-based company agreed to provide Medicare recipients with its weight-loss medications Zepbound and orforglipron, marketed as Foundayo, for no more than $50 monthly, plus additional reductions for cash-paying patients through LillyDirect.
Zepbound multidose pens will cost $299 monthly at the lowest dosage, with higher doses priced up to $449, while Foundayo will start at $149 monthly for the lowest dose via LillyDirect.
The company will also make Emgality, a migraine medication, available at $299 per pen, and Trulicity, a diabetes treatment, at $389 monthly through TrumpRx.
ABBVIE
The Illinois-based pharmaceutical company agreed in January to lower medication prices through Medicaid and expand direct-to-consumer availability via TrumpRx for treatments including Humira and Synthroid.
BRISTOL MYERS SQUIBB
In December, the company announced it will supply its popular blood-thinner Eliquis to Medicaid recipients at no cost as part of its Trump administration agreement.
The company also committed to donating more than seven tons of active pharmaceutical ingredients for Eliquis production.
GILEAD SCIENCES
In December, the biopharmaceutical company stated it will offer selected treatments for HIV, hepatitis C, hepatitis B, and COVID-19 at reduced prices for Medicaid recipients.
The company committed to pricing future medications equally with other major developed nations and making its hepatitis C treatment, Epclusa, available at discounted cash prices through TrumpRx and its own patient program.
EMD SERONO
In October, the German pharmaceutical unit and Trump administration announced the company would sell fertility treatments, including Gonal-f, Ovidrel, and Cetrotide, directly to patients with an 84% combined discount off list prices when all three are used for IVF procedures.
The company committed to offering all new U.S. drug launches at prices matching those charged in other developed nations.
MERCK
In December, the American pharmaceutical company announced it will sell diabetes medications Januvia, Janumet, and Janumet XR — which face generic competition next year — directly to consumers at approximately 70% below list prices.
If approved, the company’s experimental cholesterol medication enlicitide will also be available through direct-to-consumer channels, including TrumpRx.
ROCHE
In December, the Swiss company’s Genentech division stated it would reduce prices for many medications under Medicaid to levels comparable with those in other wealthy nations.
The company also agreed to offer influenza treatments through TrumpRx.gov and its own direct-patient program.
NOVARTIS
In December, the Swiss pharmaceutical giant committed to launching new medications in the United States at prices comparable to other developed countries.
The company also agreed to make multiple sclerosis drug Mayzent and cancer treatments Rydapt and Tabrecta available through its direct-patient platform and TrumpRx.gov.
AMGEN
The biotechnology company stated it will add cholesterol medication Repatha at $239 monthly, migraine treatment Aimovig, and arthritis drug Amjevita at $299 monthly to its direct-patient program, representing 60% to 80% reductions from list prices.
SANOFI
In December, the French pharmaceutical company committed to providing lower-cost medications via TrumpRx and other direct-patient platforms, with average savings of approximately 70% on treatments for infections, heart conditions, and diabetes.
The company also agreed to align Medicaid pricing for several medications with rates in other high-income countries.
GSK
In December, the British pharmaceutical company agreed to make most inhaled respiratory treatments and other medications available to patients through a direct-patient platform with savings reaching 66%.
The company also committed to reducing prices for certain Medicaid medications and launching new drugs with a “more balanced pricing approach” across developed nations.
BOEHRINGER INGELHEIM
In December, the German pharmaceutical company stated it would make its medications available through TrumpRx.gov at discounted rates.
REGENERON
In April, the biotechnology company indicated it expects to announce an agreement with the Trump administration “in the near future.”
Among the 17 major pharmaceutical companies that received correspondence from President Trump in July, it remains the only one that has not finalized such an agreement.
